China Cord Blood

Hong Kong, China Founded: 2003 • Age: 23 yrs
Biobanking services for umbilical cord blood stem cells are provided.

About China Cord Blood

China Cord Blood is a company based in Hong Kong (China) founded in 2003.. China Cord Blood has completed 1 acquisition, including Cellenkos. China Cord Blood offers products and services including Bocoran Terpercaya and Rekapan Result Toto. China Cord Blood operates in a competitive market with competitors including StemCyte, Generate, LaCell, Forever Labs and Provia Labs, among others.

  • Headquarter Hong Kong, China
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $65 M (USD), Post-IPO

    Apr 28, 2012

  • Investors
    KKR

    & 1 more

  • Employee Count
    Employee Count
  • Investments & Acquisitions
  • Acquired by

    (Dec 30, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of China Cord Blood

China Cord Blood offers a comprehensive portfolio of products and services, including Bocoran Terpercaya and Rekapan Result Toto. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Delivers accurate Toto number predictions based on statistical patterns.

Provides real-time recaps of Toto results for quick user access.

Funding Insights of China Cord Blood

  • Total Funding
  • Total Rounds 2
  • Last Round Post-IPO — $65.0M
  • First Round
  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2012 Amount Post-IPO - China Cord Blood Valuation

investors

KKR
Jun, 2007 Amount Private Equity Round - China Cord Blood Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in China Cord Blood

China Cord Blood has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include KKR and EW Healthcare Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Multiple sectors are invested in by this private equity firm.
Founded Year Domain Location
Growth-stage healthcare companies are invested in by EW Healthcare Partners.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by China Cord Blood

China Cord Blood has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Cellenkos. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
T-cell therapeutics are developed for autoimmune and inflammatory diseases.
2016
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - China Cord Blood

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

China Cord Blood Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of China Cord Blood

China Cord Blood operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as StemCyte, Generate, LaCell, Forever Labs and Provia Labs, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Umbilical cord blood stem cell transplantation and therapeutic products company
domain founded_year HQ Location
Provider of services for the storage of stem cells
domain founded_year HQ Location
Stem Cell Production
domain founded_year HQ Location
Stem cells are stored and preserved for future therapeutic applications.
domain founded_year HQ Location
Stem cell biobanking and manufacturing from children's teeth are provided.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on China Cord Blood

Frequently Asked Questions about China Cord Blood

When was China Cord Blood founded?

China Cord Blood was founded in 2003 and raised its 1st funding round 4 years after it was founded.

Where is China Cord Blood located?

China Cord Blood is headquartered in Hong Kong, China.

Who is the current CEO of China Cord Blood?

Arashiyama Rui is the current CEO of China Cord Blood.

What does China Cord Blood do?

Founded in 2003 and based in Hong Kong, China, the company operates in the biobanking sector focused on umbilical cord blood stem cells. Storage services are offered to parents for preserving cord blood stem cells from newborns. Operations center on collection, processing, and long-term cryopreservation of these cells for potential medical use. The domain globalcordbloodcorp.com is utilized for its online presence. Leadership includes co-CEOs Arashiyama Rui and Zheng Ting.

Who are the top competitors of China Cord Blood?

China Cord Blood's top competitors include StemCyte, Forever Labs and LaCell.

What products or services does China Cord Blood offer?

China Cord Blood offers Bocoran Terpercaya and Rekapan Result Toto.

How many acquisitions has China Cord Blood made?

China Cord Blood has made 1 acquisition, including Cellenkos.

Who are China Cord Blood's investors?

China Cord Blood has 2 investors. Key investors include KKR, and EW Healthcare Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available